.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

American Conference Institute: Summit on Biosimilars & Innovator Biologics

ACI Panelists Discuss Misaligned Incentives in the Biosimilars Market

July 15th 2021

Article

Panelists at the American Conference Institute's 2021 meeting took on the complexities of biosimilar adoption in a wide-ranging discussion.

Amgen Executive Weighs the Challenges for Interchangeable Biosimilars

June 25th 2021

Article

A turning point for interchangeable biosimilars has arrived, as the first may be approved this year, but many questions about these agents have yet to be answered, according to Laura Sim, senior counsel for Amgen.

Pharmaceutical Pay-for-Delay Settlements "Have a Good Side"

June 23rd 2021

Article

Pay-for-delay settlements between drug companies are better regulated than in the past and are in danger of being overregulated, one panelist said.